Today’s deal net captures the smaller investments from across the university innovation ecosystem over the past two weeks.
Pathios Therapeutics, a UK-based autoimmune diseases and cancer-focused drug developer, has collected $8.8m in a series A round featuring Medical Research Commercialisation Fund, the an Australian government-backed initiative investing in technologies from more than 50 Australia and New Zealand-based research institutions and hospitals. The round also included venture capital firm Canaan. In addition to the funding round, Pathios also announced the appointment of Stuart Hughes, former senior director and head of pharmacology at biopharmaceutical firm Vertex Pharmaceuticals, as its chief…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
